Boston Scientific (NYSE:BSX - Get Free Report) issued an update on its fourth quarter 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.770-0.790 for the period, compared to the consensus EPS estimate of 0.760. The company issued revenue guidance of $5.2 billion-$5.3 billion, compared to the consensus revenue estimate of $5.2 billion. Boston Scientific also updated its FY 2025 guidance to 3.020-3.040 EPS.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Needham & Company LLC reiterated a "buy" rating and set a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Barclays lifted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Finally, Wells Fargo & Company increased their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average price target of $121.61.
Get Our Latest Report on Boston Scientific
Boston Scientific Price Performance
NYSE:BSX opened at $99.88 on Wednesday. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $109.50. The firm has a market cap of $148.00 billion, a price-to-earnings ratio of 59.45, a price-to-earnings-growth ratio of 2.42 and a beta of 0.61. The company's 50-day moving average is $101.19 and its two-hundred day moving average is $101.83. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.
Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific will post 2.85 EPS for the current year.
Insiders Place Their Bets
In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $17,972,457 over the last ninety days. Company insiders own 0.50% of the company's stock.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in BSX. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the period. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter worth $26,000. Main Street Financial Solutions LLC raised its stake in shares of Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock valued at $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC lifted its holdings in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock valued at $13,275,000 after acquiring an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC boosted its position in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock worth $763,000 after purchasing an additional 2,556 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
